Nonacog alfa

Drug Profile

Nonacog alfa

Alternative Names: BeneFIX; Blood-coagulation-factor-IX-synthetic-human; Coagulation Factor IX (Recombinant) - Pfizer; Factor IX - Wyeth; Factor-IX-Genetics-Institute; Recombinant Factor IX - Wyeth

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Oxford; Washington Research Foundation
  • Developer Grifols; Pfizer
  • Class Antihaemorrhagics; Blood coagulation factors
  • Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Haemophilia-B in China (IV, Infusion)
  • 05 Aug 2016 Takeda and Pfizer terminates its commercialisation agreement for nonacog alfa in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top